ADRO down 41% Thinly traded small cap Aduro Biotech (NASDAQ:ADRO) is down 24% premarket on light volume in apparent reaction to Merck's announcement of preliminary Phase 1 data on STING agonist MK-1454 at ESMO in Munich. The response rate was 0% in the monotherapy arm in patients with solid tumors or lymphomas.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.